Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Trevi Therapeutics (NASDAQ:TRVI) and maintained a price target of $8.
October 04, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Trevi Therapeutics and maintained a price target of $8, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst suggests a positive outlook for Trevi Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100